Shire PLC (LON:SHP)‘s stock had its “outperform” rating reiterated by Credit Suisse Group AG in a note issued to investors on Friday. They currently have a GBX 5,200 ($64.41) target price on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price objective points to a potential upside of 2.30% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. HSBC lowered their price target on Shire PLC from GBX 5,250 ($65.03) to GBX 5,200 ($64.41) and set a ” hold” rating on the stock in a report on Wednesday, September 28th. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Deutsche Bank AG reissued a “buy” rating and set a GBX 6,000 ($74.32) price target on shares of Shire PLC in a report on Wednesday, August 3rd. Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a report on Friday, July 22nd. Finally, Liberum Capital reaffirmed a “buy” rating and issued a GBX 5,500 ($68.13) target price on shares of Shire PLC in a report on Friday, July 29th. One investment analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 5,992.27 ($74.23).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) opened at 5083.00 on Friday. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,562.83. The firm’s 50-day moving average price is GBX 4,980.23 and its 200 day moving average price is GBX 4,690.21. The company’s market cap is GBX 45.76 billion.

In other news, insider Dominic Blakemore acquired 133 shares of the firm’s stock in a transaction on Friday, September 30th. The stock was acquired at an average price of GBX 5,010 ($62.06) per share, with a total value of £6,663.30 ($8,253.81).

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.